Generated by All in One SEO v5.0.1.1, this is an llms.txt file, used by LLMs to index the site.

# Osteosarcoma Now

Development Website

## Sitemaps

- [XML Sitemap](https://osteosarcomanow.org/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [New Phase III Osteosarcoma Trial Reports Positive Results](https://osteosarcomanow.org/new-phase-iii-osteosarcoma-trial-reports-positive-results/) - [et_pb_section fb_built=”1″ theme_builder_area=”post_content” _builder_version=”4.27.4″ _module_preset=”default”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content”][et_pb_column _builder_version=”4.27.4″ _module_preset=”default” type=”4_4″ theme_builder_area=”post_content”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content” hover_enabled=”0″ sticky_enabled=”0″]There has been encouraging news from a Phase III clinical trial investigating a new treatment for people with relapsed or refractory osteosarcoma. What is the treatment? The treatment, called Ris-Rez (risvutatug rezetecan), is a type of targeted therapy known
- [Announcing the Relaunch of our Osteosarcoma Clinical Trial Database](https://osteosarcomanow.org/announcing-the-relaunch-of-our-osteosarcoma-clinical-trial-database/) - [et_pb_section fb_built=”1″ theme_builder_area=”post_content” _builder_version=”4.27.4″ _module_preset=”default” min_height=”809.6px”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content” custom_padding=”0px||0px|||”][et_pb_column _builder_version=”4.27.4″ _module_preset=”default” type=”4_4″ theme_builder_area=”post_content”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content” hover_enabled=”0″ sticky_enabled=”0″ min_height=”469.6px”]At Osteosarcoma Now, our mission has always been to make trusted information about osteosarcoma accessible to everyone. Today, we are proud to relaunch our Clinical Trial Explorer (ONTEX) following a major redevelopment that transforms how clinical
- [OST-HER2 Update: New FDA Milestone](https://osteosarcomanow.org/ost-her2-new-fda-milestone-for-osteosarcoma/) - [et_pb_section fb_built=”1″ theme_builder_area=”post_content” _builder_version=”4.27.4″ _module_preset=”default”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content”][et_pb_column _builder_version=”4.27.4″ _module_preset=”default” type=”4_4″ theme_builder_area=”post_content”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content” hover_enabled=”0″ sticky_enabled=”0″]Osteosarcoma Now has been following the development of OST-HER2, one of the most advanced investigational therapies currently being developed specifically for osteosarcoma. Over the past three years, we have reported on the progression of the Phase 2b clinical trial,
- [How Dogs Could Help Unlock New Treatments for Osteosarcoma](https://osteosarcomanow.org/how-dogs-could-help-unlock-new-treatments-for-osteosarcoma/) - [et_pb_section fb_built=”1″ theme_builder_area=”post_content” _builder_version=”4.27.4″ _module_preset=”default”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content”][et_pb_column _builder_version=”4.27.4″ _module_preset=”default” type=”4_4″ theme_builder_area=”post_content”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content” hover_enabled=”0″ sticky_enabled=”0″] Tufts University Joins Global Effort to Find Better Treatments for Osteosarcoma Veterinary oncologists at Tufts University are part of the largest coordinated osteosarcoma research initiative ever launched, using clinical trials in pet dogs to generate insights that could
- [New Research on Osteosarcoma Lung Metastasis](https://osteosarcomanow.org/new-research-on-osteosarcoma-lung/) - [et_pb_section fb_built=”1″ theme_builder_area=”post_content” _builder_version=”4.27.4″ _module_preset=”default”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content” custom_padding=”1px|||||”][et_pb_column _builder_version=”4.27.4″ _module_preset=”default” type=”4_4″ theme_builder_area=”post_content”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content” hover_enabled=”0″ sticky_enabled=”0″ text_font_size=”18px”]Research focuses on how osteosarcoma reaches the lungs and what may prevent it A research team at Oregon Health and Science University (OHSU) has been awarded $3.17 million from the National Institutes of Health to develop new
- [Cabozantinib in Osteosarcoma: What We Know So Far](https://osteosarcomanow.org/cabozantinib-in-osteosarcoma-what-we-know-so-far/) - [et_pb_section fb_built=”1″ theme_builder_area=”post_content” _builder_version=”4.27.4″ _module_preset=”default”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content” custom_padding=”0px|||||”][et_pb_column _builder_version=”4.27.4″ _module_preset=”default” type=”4_4″ theme_builder_area=”post_content”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content” hover_enabled=”0″ sticky_enabled=”0″] Treatment for osteosarcoma has remained largely unchanged for decades, particularly for patients with metastatic or relapsed disease. Targeted therapies are now being explored as a way to improve outcomes. One of these is cabozantinib, a drug currently
- [New Hope in Preventing Osteosarcoma Lung Metastasis](https://osteosarcomanow.org/55479-2/) - [et_pb_section fb_built=”1″ theme_builder_area=”post_content” _builder_version=”4.27.4″ _module_preset=”default”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content”][et_pb_column _builder_version=”4.27.4″ _module_preset=”default” type=”4_4″ theme_builder_area=”post_content”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content” hover_enabled=”0″ sticky_enabled=”0″]New Research Exploring FAK Inhibitors to Prevent Osteosarcoma Lung Metastasis Researchers are exploring a new strategy to stop osteosarcoma from spreading to the lungs, one of the biggest challenges in treating this aggressive bone cancer. A team at
- [Osteosarcoma Now Webpage Launch](https://osteosarcomanow.org/osteosarcoma-now-webpage-launch/) - We are delighted to launch Osteosarcoma Now, the latest step for the Myrovlyits Trust in providing osteosarcoma patients and their families with information, support and choice. In 2021 we looked into using our experience and knowledge to support other rare cancers in which we could help. We were touched by a personal story of an
- [Looking Ahead to 2026 Reflections on a Year of Change at Osteosarcoma Now](https://osteosarcomanow.org/looking-ahead-to-2026-reflections-on-a-year-of-change-at-osteosarcoma-now/) - [et_pb_section fb_built=”1″ theme_builder_area=”post_content” _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”3px|||||”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content” hover_enabled=”0″ sticky_enabled=”0″][et_pb_column _builder_version=”4.27.4″ _module_preset=”default” type=”4_4″ theme_builder_area=”post_content”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content” hover_enabled=”0″ sticky_enabled=”0″] In March 2025, we sadly lost the founder of the Osteosarcoma Now. His close personal connection to osteosarcoma led them to support the development of Osteosarcoma Now by funding the creation of the website and
- [A New Step Forward: Targeting SFRP2 to Overcome Osteosarcoma Treatment Resistance co-funded by the Bardo Foundation](https://osteosarcomanow.org/a-new-step-forward-targeting-sfrp2-to-overcome-osteosarcoma-treatment-resistance-co-funded-by-the-bardo-foundation/) - [et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]We are delighted to share an important milestone in osteosarcoma research and in the journey of The Bardo Foundation. A new scientific paper, co-funded by the Bardo Foundation with the Myrovlytis Trust, has been published. It marks the first-ever published paper
- [Osteosarcoma Now Joins the Bardo Foundation|Advancing Support](https://osteosarcomanow.org/osteosarcoma-now-joins-the-bardo-foundationadvancing-support/) - [et_pb_section fb_built=”1″ theme_builder_area=”post_content” _builder_version=”4.27.4″ _module_preset=”default”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content”][et_pb_column _builder_version=”4.27.4″ _module_preset=”default” type=”4_4″ theme_builder_area=”post_content”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content” hover_enabled=”0″ sticky_enabled=”0″]We are excited to announce that Osteosarcoma Now has transitioned to ownership under The Bardo Foundation. This change represents a significant opportunity for advancement, while preserving the mission and core values that unite our community. We extend sincere appreciation to the
- [New Study Links Nerve Growth and Blood Vessels to Osteosarcoma Progression](https://osteosarcomanow.org/new-study-links-nerve-growth-and-blood-vessels-to-osteosarcoma-progression/) - [et_pb_section fb_built=”1″ theme_builder_area=”post_content” _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ sticky_enabled=”0″][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content”][et_pb_column _builder_version=”4.27.4″ _module_preset=”default” type=”4_4″ theme_builder_area=”post_content”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content” hover_enabled=”0″ sticky_enabled=”0″] Scientists at Johns Hopkins Medicine have uncovered an unexpected link between the nervous system and bone cancer growth. Their new study suggests that the nerves which carry pain signals might also be helping osteosarcoma tumours grow
- [Combining drugs to treat osteosarcoma – research project](https://osteosarcomanow.org/combination-drugs-to-treat-osteosarcoma-research-project/) - We have co-funded a project with The Bardo Foundation that looks at a new drug for osteosarcoma. The drug has been developed by Professor Nancy DeMore (Medical University of South Carolina). It is a monoclonal antibody (mAB) against the protein SFRP2. They hope this drug will improve outcomes for osteosarcoma patients. ‘We’re really passionate about
- [Mifamurtide after Surgery in Osteosarcoma: Who Might Benefit?](https://osteosarcomanow.org/55281-2/) - [et_pb_section fb_built=”1″ theme_builder_area=”post_content” _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”0px|||||” custom_margin=”||-84px|||”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content” min_height=”57px”][et_pb_column _builder_version=”4.27.4″ _module_preset=”default” type=”4_4″ theme_builder_area=”post_content”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content” hover_enabled=”0″ sticky_enabled=”0″]Mifamurtide after Surgery in Osteosarcoma: Who Might Benefit?[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content” custom_padding=”31px||0px|||” custom_margin=”-51px|auto||auto||”][et_pb_column _builder_version=”4.27.4″ _module_preset=”default” type=”4_4″ theme_builder_area=”post_content”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” theme_builder_area=”post_content” hover_enabled=”0″ sticky_enabled=”0″ custom_padding=”0px|||||”]A new analysis from Italy and Spain looked at almost 400 people (ages 4–40)
- [Nivoluab and Sunitinib: a combination therapy for progressive bone sarcomas](https://osteosarcomanow.org/nivoluab-and-sunitinib-a-combination-therapy-for-progressive-bone-sarcomas/) - Treatment for progressing bone sarcomas can be challenging. This is especially true after patients have had drugs to treat cancer but the cancer is still progressing. A potential combination therapy of immunotherapy and TKI inhibitor treatment could help improve results for people with progressing bone sarcomas. This includes osteosarcoma. An approach which may work includes
- [The LEN-IE protocol for managing osteosarcoma: a small-scale trial](https://osteosarcomanow.org/the-len-ie-protocol-for-managing-osteosarcoma-a-small-scale-trial/) - Osteosarcoma (OS) is the most common bone cancer in children and young adults. It is more common in those aged 10 to 19 years. It affects about 3.4 people per million each year worldwide. This cancer comes back in 30% to 40% patients with localized disease. It returns in 80% of those with cancer that
- [miRNAs and Osteosarcoma Treatment: What is possible?](https://osteosarcomanow.org/mirnas-and-osteosarcoma-treatment-what-is-possible/) - miRNAs – what are they? Ribonucleic acid is also known as RNA. It is a cell building block that is in all living cells and has structural similarities to DNA. Three different types of RNA exist in cells: Messenger RNA (mRNA), Ribosomal RNA (rRNA) Transfer RNA (tRNA). In this blog we will look at mRNA
- [Tailoring osteosarcoma treatment by using population level data: a nomogram explainer](https://osteosarcomanow.org/tailoring-osteosarcoma-treatment-by-using-population-level-data-a-nomogram-explainer/) - Patients with osteosarcoma (OS) which has spread to the lungs (lung metastasised osteosaroma, or LMOS) have poor survival rates. Nomograms are a form of predictive technology used in medicine. They are particularl3 This randomized control trial looked at risk factors of LMOS. This was so the doctors would be able to better support those with
- [Long term outcomes in osteosarcoma treatment: a 25 year follow up of the OSAD93 trial](https://osteosarcomanow.org/long-term-outcomes-in-osteosarcoma-treatment-a-25-year-follow-up-of-the-osad93-trial/) - The trial in this blog was originally undertaken in the mid-1990s. The trial followed up the patients who received the treatment after the trial for 25 years. This paper follows up the participants from the original trial and is one of the longest follow up osteosarcoma trials currently known. Osteosarcoma (OS) requires multiple forms of
- [Targeting Osteosarcoma with Anti-CD3 and Anti-GD2 Immunotherapy](https://osteosarcomanow.org/targeting-osteosarcoma-with-anti-cd3-and-anti-gd2-immunotherapy/) - What is this trial about? It is well known that osteosarcoma (OS) treatments have had limited success in helping patients with the disease. Previous research shows you can ’arm’ T-cells with a special molecule called GD2-specific antibody. GD2 is protein found in nearly all OS cells. CD3 is a glycoprotein in T cells. CD3-specific and
- [Combining therapies: MASCT-I, TKI and ICI in a therapeutic approach to treating sarcomas](https://osteosarcomanow.org/combining-therapies-masct-1-tki-and-ici-in-a-therapeutic-approach-to-treating-sarcomas/) - Bone and soft tissue sarcomas are known to have poor treatment response and outcomes. The standard treatment of surgery alongside chemotherapy and radiotherapy often does not resolve the disease. At least 40% people who have these treatments will develop cancer that has grown back (recurrent) or spread to other parts of the body (metastatic). Treatment
- [Recurrent and Refractory Osteosarcoma: What do the clinical trials tell us about future research?](https://osteosarcomanow.org/recurrent-and-refractory-osteosarcoma-what-do-the-clinical-trials-tell-us-about-future-research/) - The FOSTER consortium (Fight Osteosarcoma Through European Research) aims to connect clinicians, researchers, and patient advocates across Europe to improve clinical research in Osteosarcoma (OS). In this research, members of the FOSTER Consortium looked at OS clinical trials that were published over a period of 19 years. This is to gain an understanding on the
- [Surgical approaches to lung-metastasised osteosarcoma: What improves patient outcomes?](https://osteosarcomanow.org/surgical-approaches-to-lung-metastasised-osteosarcoma-what-improves-patient-outcomes/) - In this blog we look at a study by Kuo et al, where the results will be used for a larger ongoing Children’s Oncology Group Trial. The larger trial is looking at surgical outcomes for patients with osteosarcoma (OS) which has spread to the lungs (NCT05235165/ AOST2031). OS is a rare type of cancer, and
- [A Look at TKI Therapy: A Treatment Strategy for Osteosarcoma](https://osteosarcomanow.org/a-look-at-tki-therapy-a-treatment-strategy-for-osteosarcoma/) - Osteosarcoma is an aggressive form of bone cancer which progresses quickly. Treatment for osteosarcoma has remained the same for around 40 years. New avenues of treatment need to be researched and trialled to improve outcomes for patients.One path for treatment includes combining medicines that target weaknesses in cancer cells. This is compared to standard chemotherapy
- [Exploring new horizons in osteosarcoma treatment](https://osteosarcomanow.org/exploring-new-horizons-in-osteosarcoma-treatment/) - [et_pb_section fb_built=”1″ _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}” min_height=”1392.9px”][et_pb_row _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}” min_height=”1321.4px”][et_pb_column type=”4_4″ _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.14.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Exploring new horizons in osteosarcoma treatment Osteosarcoma is the most common form of bone cancer in young people. It has long posed challenges to medical professionals trying to find an effective treatment. Despite advances in cancer treatment,
- [The FOSTER Website – Funding Announcement](https://osteosarcomanow.org/the-foster-website-funding-announcement/) - We are pleased to announce that we have funded the creation and maintenance of the FOSTER consortium website. In the last 30 years there has been little change to osteosarcoma treatment or survival. We now have an opportunity to change this through the FOSTER (Fight Osteosarcoma Through European Research) consortium. With 265 members across 19
- [Can treatment for osteosarcoma be effective for other bone cancers?](https://osteosarcomanow.org/can-treatment-for-osteosarcoma-be-effective-for-other-bone-cancers/) - Rare primary malignant bone sarcoma (RPMBS) is a term for rare bone cancers, and they account for no more than a tenth of fast-growing bone tumours. It can be difficult to research RPMBS as they are so rare. This slows down the development of new treatments. RPMBS also usually affect an older adult population. This
- [Finding drugs to treat metastatic bone cancer](https://osteosarcomanow.org/finding-drugs-to-treat-metastatic-bone-cancer/) - We were delighted to award Dr Tanya Heim a travel grant to present her work at FACTOR. Find out more about her work and FACTOR in her guest blog post. I have been a biomedical research scientist for over a decade. I have not always studied cancer, but I have always been interested in rare
- [Making it Better for Young People with Osteosarcoma Together](https://osteosarcomanow.org/making-it-better-for-young-people-with-osteosarcoma-together/) - Making it better for young people with Osteosarcoma is the mission of MIB Agents. Every year they bring together patients, families, doctors and researchers to drive forward research into bone cancer. This June the conference, called FACTOR, took place in Atlanta and we were delighted to attend. In this blog we highlight some of the
- [Hunting for Protein Changes in Bone Cancer](https://osteosarcomanow.org/hunting-for-protein-changes-in-bone-cancer/) - We were delighted to award Dr Wolfgang Paster a travel grant to present his work at the 20th Annual Meeting of Cancer Immunotherapy earlier this year. Find out more about his work in his guest blog post.
- [Osteosarcoma Clinical Trial Update](https://osteosarcomanow.org/osteosarcoma-clinical-trial-update/) - Every year cancer experts from across the world come together for The American Society of Clinical Oncology Annual Meeting (ASCO). The aim of ASCO is to share knowledge and provide updates on cancer research. By working together we hope to develop new cancer treatments. In today’s blog, we will discuss some of the early results
- [Osteosarcoma Now is PIF TICK accredited](https://osteosarcomanow.org/leicester-university-research-group-make-major-breakthrough/) - The Myrovlytis Trust, the Charity that runs Osteosarcoma Now, has been awarded the PIF TICK – the UK’s only quality mark for print and online health information. To become a ‘trusted information creator’, The Myrovlytis Trust had to undergo an assessment showing it met 10 key criteria. This means you can be assured that what
- [Osteosarcoma: The research highlights of 2021](https://osteosarcomanow.org/osteosarcoma-the-research-highlights-of-2021/) - Sarcoma Patients EuroNet Association (SPAEN) hosted a fantastic meeting this week about key scientific advances in sarcoma during 2021. The session discussed new drugs, surgery, and radiotherapy (RT) in osteosarcoma. Medical oncologist Nathalie Gasper took the floor first. She discussed a group of drugs called multi tyrosine kinase inhibitors (mTKIs). mTKIs block multiple kinases (proteins
- [British Sarcoma Group Meeting Highlights](https://osteosarcomanow.org/british-sarcoma-group-meeting-highlights/) - We attended and exhibited at the British Sarcoma Group (BSG) meeting on 23rd-24th March in Liverpool, UK. It was inspiring to learn about the research and resources being created to support sarcoma patients. We were also delighted to be part of the charity hub alongside Sarcoma UK, BCRT and GIST Cancer UK. In this
- [Targeting the Immune System to Treat Osteosarcoma – Research Project](https://osteosarcomanow.org/targeting-the-immune-system-to-treat-osteosarcoma-research-project/) - We are funding a project looking at using immunotherapy (IMT) to treat osteosarcoma. The project is led by Professor Graham Cook and Dr Fiona Errington-Mais (University of Leeds, UK). The body’s immune system is best known for protecting us from infections. However, it also attacks cancer cells, killing them before they can cause a problem. Some
- [Interview: Count Me In Osteosarcoma Project](https://osteosarcomanow.org/interview-count-me-in-osteosarcoma-project/) - The Count Me In Osteosarcoma Project is a study which aims to speed up research into osteosarcoma. Patients can take part in the project by sharing experiences and medical data. The data will be studied by scientists who can use it to better understand osteosarcoma. The hope is that this project will help to find
- [Predicting outcomes in osteosarcoma: new markers found](https://osteosarcomanow.org/predicting-outcomes-in-osteosarcoma-new-markers-found/) - A recent study has found new markers in the body that may be able to predict how a patient’s osteosarcoma (OS) will progress. This is important as predicting how cancer behaves helps doctors to create treatment plans. It also gives patients more certainty in what can be a very difficult time. In recent years scientists
- [Can dogs smell bone cancer?](https://osteosarcomanow.org/can-dogs-smell-bone-cancer/) - In recent years there has been a lot of research into new less invasive techniques to detect cancer early. One of these techniques is training dogs to sniff out cancer. People with cancer may produce specific smells that cannot be detected by the human nose. Dogs on the other hand may be able to detect
- [Towards Drug Discovery](https://osteosarcomanow.org/towards-drug-discovery/) - There is an urgent need to find new treatments for osteosarcoma (OS) with less harmful side effects. To do this we need to find drugs that specifically target OS and not the other cells in the body. A recent study led by Professor Richard Gorlick (MD Anderson, USA) found several new proteins on the surface
- [Paediatric Cancer Data Commons: Making Data Impactful](https://osteosarcomanow.org/paediatric-cancer-data-commons-making-data-impactful/) - We were delighted to attend the 3rd annual Paediatric Cancer Data Commons (PCDC) webinar and find out how the PCDC is impacting research into childhood cancers. The PCDC is an exciting platform for combining and sharing data about childhood cancer. Osteosarcoma (OS) is one of the cancers in the PCDC. The project is led by
- [Bone Cancer Conference: The Research Highlights](https://osteosarcomanow.org/bone-cancer-conference-the-research-highlights/) - We were delighted to attend the Bone Cancer Research Trust (BCRT) support and information conference. The conference connected patients, family members, scientists and healthcare workers and was a fantastic opportunity to learn from one another. Patient advocates shared their inspiring stories, scientists discussed their research and the BCRT showcased their patient-focused resources. This is the
- [The Bone Cancer Conference: Resources and Patient Stories.](https://osteosarcomanow.org/the-bone-cancer-conference-resources-and-patient-stories/) - We were delighted to attend the Bone Cancer Research Trust (BCRT) support and information conference on Saturday 21st May. The conference connected patients, family members, scientists and healthcare workers and was an opportunity to learn from one another. This is the second of a two-part blog sharing some of the lessons learned from patients and
- [Curated Osteosarcoma Clinical Trial Database](https://osteosarcomanow.org/curated-osteosarcoma-clinical-trial-database/) - We are delighted to launch our curated osteosarcoma clinical trial database. We believe that wherever you live in the world information about clinical trials should be available to you and this database has been built to support your search. Each trial has been summarised in accessible language to give a clear picture of its aims,
- [Your Osteosarcoma Healthcare Team  ](https://osteosarcomanow.org/your-osteosarcoma-healthcare-team/) - When you are diagnosed with osteosarcoma (OS), you will often see many different types of doctors in a very short period of time. We understand this may be confusing especially when you’ve just been diagnosed with OS and don’t know where to start. In this blog we break down the types of healthcare workers you
- [Inhaled IL-15 - A New Route for Osteosarcoma Treatment](https://osteosarcomanow.org/inhaled-il-15-a-new-route-for-osteosarcoma-treatment/) - Just like humans, dogs can develop osteosarcoma (OS) and take part in clinical trials. Not only do these trials give owners access to new drugs for their pets, but the results may help to inform research into new treatments for people with OS. A recent phase 1 trial led by Dr Robert J. Canter (University
- [Osteosarcoma Modelling gets an Upgrade with Stem Cells and Genetic Engineering](https://osteosarcomanow.org/osteosarcoma-modelling-gets-an-upgrade-with-stem-cells-and-genetic-engineering/) - The genetics of osteosarcoma is complex. Kelsie is developing a new osteosarcoma model where she controls how it starts and can watch its progression. This will help to see what is driving osteosarcoma.
- [Osteosarcoma Now on Rare Disease Podcast](https://osteosarcomanow.org/osteosarcoma-now-on-rare-disease-podcast/) - This year we were invited to take part in the rare disease podcast “Wait, How Do You Spell That?” run by Patient Worthy. Patient Worthy is an online platform that shares news stories that are important to the rare disease community and connects them with educational resources. In the podcast, CEO Anna Webb and Charity
- [Overcoming the Challenges of CAR T Therapy in Osteosarcoma](https://osteosarcomanow.org/overcoming-the-challenges-of-car-t-therapy-in-osteosarcoma/) - CAR T therapy has had excellent results in blood cancers but has not yet worked in solid cancer types. This blog discusses the challenges in using CAR T therapy in osteosarcoma, as well as approaches to overcoming them.
- [Using Cancer Busting Viruses to Treat Bone Cancer](https://osteosarcomanow.org/using-cancer-bursting-viruses-to-treat-bone-cancer/) - Oncolytic ‘cancer busting’ viruses are a type of immunotherapy. They can kill cancer cells directly and by activating the body’s immune system to fight cancer.
- [What We Can Learn from Recent Osteosarcoma Clinical Trials](https://osteosarcomanow.org/what-we-can-learn-from-recent-osteosarcoma-clinical-trials/) - Two trials have been published looking at new treatments in osteosarcoma. Although the drugs were not effective there is a lot that can be learned from them.
- [Highlights from the MIB Agents FACTOR Conference](https://osteosarcomanow.org/highlights-from-the-mib-agents-factor-conference/) - We attended the MIB Agents FACTOR conference. The osteosarcoma community joined forces for an inspirational cause – to make things better.
- [ICONIC: A Recruiting Osteosarcoma Trial](https://osteosarcomanow.org/iconic-a-recruiting-osteosarcoma-trial/) - Dr Strauss is one of the UK's leading researchers in osteosarcoma and is leading the ICONIC trial. We interviewed her about the importance of the trial.
- [<strong>Understanding How Osteosarcoma Spreads</strong>](https://osteosarcomanow.org/understanding-how-osteosarcoma-spreads/) - Understanding how osteosarcoma spreads could help future treatment strategies. A paper was published identifying a protein involved in this called P2RX7B.
- [Sign Up for the Osteosarcoma Now Newsletter](https://osteosarcomanow.org/sign-up-for-the-osteosarcoma-now-newsletter/) - We are excited to announce that the first Osteosarcoma Now Newsletter (ONN) will be in your inbox on Friday 30th September. Sign up now!
- [Osteosarcoma Research at Sarcoma UK](https://osteosarcomanow.org/osteosarcoma-research-at-sarcoma-uk/) - This week Kate Quillin, Research Officer at Sarcoma UK, took over our blog. Sarcoma UK fund vital research, offer support and campaign for better treatments.
- [Targeting Cancer Survival Mechanisms](https://osteosarcomanow.org/targeting-cancer-survival-mechanisms/) - A recent study explored a potential treatment called APR-246 in hard-to-treat cancers containing specific genetic mutations.
- [Could P2 Receptors Be Targets For Primary Bone Cancer Therapy?](https://osteosarcomanow.org/could-p2-receptors-be-targets-for-primary-bone-cancer-therapy/) - Primary bone cancer (PBC) is a group of cancers that includes osteosarcoma (OS). Other cancers in this group are Ewing’s sarcoma, chondrosarcoma and chordoma. There have been few advances in the treatment of PBC for the past 40 years. This means there is an urgent need to find new therapeutic strategies for PBC. There has
- [Join our Patient Advisory Board](https://osteosarcomanow.org/join-our-patient-advisory-board/) - Applications are now open to join our patient advisory board. We are looking for 6 members of the osteosarcoma community to join our board and help direct our charity's work.
- [Targeting the RB Pathway in Osteosarcoma.](https://osteosarcomanow.org/targeting-the-rb-pathway-in-osteosarcoma/) - A study has identified a new possible drug target to treat osteosarcoma. The research is in its early stages but it shows that our understanding of osteosarcoma is increasing.
- [Bone Sarcoma Peer Support - Connecting Patients](https://osteosarcomanow.org/bone-sarcoma-peer-support-connecting-patients/) - Being diagnosed with cancer can feel isolating. Bone Sarcoma Peer Support is a charity dedicated to connecting patients with shared experiences of bone cancer.
- [Immuno UK Conference Report](https://osteosarcomanow.org/immuno-uk-conference-report/) - In September 2022, we attended the Immuno UK conference. Held over 2 days in London, UK, this conference brought together over 260 people from industry and academic research. We heard the latest updates in the field of “immune oncology”. This can be described as developing therapies that use the body’s own immune system to better
- [Fighting Osteosarcoma Through Research Together](https://osteosarcomanow.org/fighting-osteosarcoma-through-research-together/) - This October clinicians, researchers and patient advocates came together for the first in-person FOSTER meeting to discuss how to advance research into osteosarcoma.
- [3D Printing in Bone Cancer Surgery](https://osteosarcomanow.org/3d-printing-in-bone-cancer-surgery/) - Surgeons are developing new techniques to aid them in removing bone cancer. One of these techniques is printing 3D models of tumours to guide the surgery.
- [Help Direct Bone Cancer Research](https://osteosarcomanow.org/help-direct-bone-cancer-research/) - The first ever global survey for bone cancer patients and carers has been launched. The aim of the survey is to advance research into bone cancer.
- [Using 3D Bioprinting to Study Osteosarcoma](https://osteosarcomanow.org/using-3d-bioprinting-to-study-osteosarcoma/) - There is a great need to develop new treatments for osteosarcoma (OS). This is particularly true for OS that has spread or has not responded to current standard therapy. Researchers are actively working towards finding new drugs to treat OS. To enable the drug development process, a deep understanding of the tumour and its microenvironment
- [Testing Existing Drugs in Osteosarcoma Models](https://osteosarcomanow.org/testing-existing-drugs-in-osteosarcoma-models/) - There is an urgent need to find new therapies in osteosarcoma (OS) that has spread or has not responded to standard treatment. Identifying new treatments can be a long and complex process. One method of speeding up the process is to use drugs that already approved to treat something else. A recent study* has just
- [Metal vs Carbon-Fibre Implants in Bone Cancer Surgery](https://osteosarcomanow.org/metal-vs-carbon-fibre-implants-in-bone-cancer-surgery/) - Surgeons may remove bone containing osteosarcoma and replace it with a metal implant. A study looked at whether carbon-fibre could be an alternative to metal.
- [CTOS Annual Meeting – The Highlights](https://osteosarcomanow.org/ctos-annual-meeting-the-highlights/) - We attended the 2022 CTOS annual meeting. The meeting brought together clinicians, researchers and patient advocates dedicated to improving outcomes in sarcoma.
- [Winter Osteosarcoma Now Newsletter](https://osteosarcomanow.org/winter-osteosarcoma-now-newsletter/) - Sign up for the Osteosarcoma Now Newsletter. Each issue will discuss the current research and signpost to events across the world.
- [Office Christmas Hours](https://osteosarcomanow.org/office-christmas-hours/) - Hello Everyone. We are closed from Friday 23rd December until Tuesday 3rd January. During that time all the content on the website will be available but we will be taking a break from the weekly blogs. On our return, we will respond to any emails. From all of us at the Myrovlytis Trust we wish
- [Osteosarcoma Now – Highlights of 2022](https://osteosarcomanow.org/osteosarcoma-now-highlights-of-2022/) - Our work in osteosarcoma started in 2021, with many months dedicated to talking with experts, patients and other charities. In this blog we reflect on what we achieved in 2022.
- [Introducing the Osteosarcoma Now Trial EXplorer (ONTEX)](https://osteosarcomanow.org/introducing-the-osteosarcoma-now-trial-explorer-ontex/) - We are delighted to launch our new improved Osteosarcoma Now Trial EXplorer (ONTEX). ONTEX is an international database that aims to make clinical trial information available and accessible to all. Each osteosarcoma clinical trial has been summarised to give a clear picture of its aims, what it involves and who can take part. It also
- [ONTEX Toolkit - Spread the Word](https://osteosarcomanow.org/ontex-toolkit-spread-the-word/) - Welcome to the ONTEX social media toolkit. We are delighted to have launched our new improved Osteosarcoma Now Trial EXplorer (ONTEX). Each osteosarcoma clinical trial has been summarised to give a clear picture of its aims, what it involves and who can take part. Its interface has been streamlined so that you can more easily
- [Harnessing the Immune System against Osteosarcoma](https://osteosarcomanow.org/harnessing-the-immune-system-against-osteosarcoma/) - In the last 30 years there has been very little change to osteosarcoma (OS) treatment. We are dedicated to changing this. Through the Myrovlytis Trust, we fund research into OS, with a focus on finding new treatments. We are pleased to announce we have awarded funding to Dr Wolfgang Paster at the Children’s Cancer Research
- [A Drug Repurposing Clinical Trial](https://osteosarcomanow.org/a-drug-repurposing-clinical-trial/) - Dr. Matteo Trucco has launched a sarcoma clinical trial. It aims to see if disulfiram could be repurposed to be used in sarcoma treatment.
- [A Close Look at the Immune Cells in Osteosarcoma](https://osteosarcomanow.org/a-close-look-at-the-immune-cells-in-osteosarcoma/) - A recent study looked at immune cells in osteosarcoma . The aim was to provide insight into the immune landscape and potentially shed some light on how it could be targeted by drugs.
- [The REGBONE Clinical Trial – Interview with Professor Anna Raciborska](https://osteosarcomanow.org/the-regbone-clinical-trial-interview-with-professor-anna-raciborsk/) - A clinical trial has opened in Poland that will test whether regorafenib can be used to treat bone cancers. We interviewed trial lead Professor Raciborsk.
- [A New Clinical Trial Testing a Drug that can Disassemble Itself - Interview with Dr Emily Slotkin](https://osteosarcomanow.org/a-new-clinical-trial-testing-a-drug-that-can-disassemble-itself/) - A clinical trial in the USA is recruiting patients with osteosarcoma and other cancers to test a new drug complex called GD2 SADA: 177 Lu DOTA. This drug uses a new technology where it can disassemble and reassemble itself. By changing the way it’s constructed it can change how it behaves in the body. The
- [A Promising New Bone Cancer Drug](https://osteosarcomanow.org/a-promising-new-bone-cancer-drug/) - Researchers have developed a new drug that works against bone cancer. The drug, called CADD522, has shown promising results in the laboratory.
- [The British Sarcoma Group Conference Highlights 2023](https://osteosarcomanow.org/the-british-sarcoma-group-conference-highlights-2023/) - The British Sarcoma Group (BSG) annual conference took place on March 22nd – 23rd 2023 in Newport, Wales. We were delighted to attend as an exhibitor to promote our Osteosarcoma Now Trial Explorer (ONTEX) and our 2023 grant funding round. It was also inspiring to hear the latest updates in the treatment of sarcomas. There

## Pages

- [Find New and Life-Changing Osteosarcoma Clinical Trials and Support Today](https://osteosarcomanow.org/) - Explore global osteosarcoma clinical trials, research, and support. Find patient-friendly information on treatments and access new therapies worldwide.
- [Osteosarcoma Clinical Trial Database](https://osteosarcomanow.org/clinical-trials/) - Search the curated osteosarcoma clinical trial database. Each trial has been summarised in accessible language to give a clear picture of its aims.
- [Preparing for Doctors Appointments](https://osteosarcomanow.org/questions-for-doctor/) - Before taking part in a clinical trial, you will have many opportunities to ask the clinical trial team questions. Here we provided advice on how to prepare for these appointments.
- [Glossary New](https://osteosarcomanow.org/glossary-2/) - Being diagnosed with osteosarcoma can feel like having to learn a whole new language. Here you can find definitions for words your doctor is likely to use.
- [About Osteosarcoma Now](https://osteosarcomanow.org/about-us/) - Osteosarcoma Now was developed with the sole purpose of supporting osteosarcoma patients and their families throughout their cancer journey, wherever they live in the world.
- [Osteosarcoma Research](https://osteosarcomanow.org/osteosarcoma-research/) - Osteosarcoma Now was developed with the sole purpose of supporting osteosarcoma patients and their families throughout their cancer journey, wherever they live in the world.
- [Donate](https://osteosarcomanow.org/donation/) - Osteosarcoma Now was developed with the sole purpose of supporting osteosarcoma patients and their families throughout their cancer journey, wherever they live in the world.
- [Blog](https://osteosarcomanow.org/blog/) - Welcome to the osteosarcoma research blog. Here you’ll find the latest news in osteosarcoma including trial results, scientific discoveries and conference reports.
- [Support Groups](https://osteosarcomanow.org/support/) - There are so many groups dedicated to supporting the osteosarcoma community. Search our interactive map for information about osteosarcoma support groups.
- [Partnerships](https://osteosarcomanow.org/partnerships/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Poppins||||||||” text_text_color=”#686868″ text_font_size=”20px” header_font=”Poppins||||||||” header_text_color=”#0E71B8″ header_2_font=”Poppins|700|||||||” header_2_text_color=”#0E71B8″ global_colors_info=”{}”] Partnerships We strongly believe that collaboration should be at the forefront of everything we do. We want to bring patients, researchers, clinicians and sarcoma charities together from across the globe to share ideas,
- [Drugs and Interventions](https://osteosarcomanow.org/drugs-and-interventions/) - [et_pb_section fb_built=”1″ disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Poppins||||||||” text_text_color=”#686868″ text_font_size=”20px” header_font=”Poppins||||||||” header_text_color=”#0E71B8″ header_2_font=”Poppins|700|||||||” header_2_text_color=”#0E71B8″ global_colors_info=”{}”] Drugs and Interventions Here we provide information on some of the treatments that have been given to patients in clinical trials. The information on this webpage provides an overview of the different
- [Checkout-Result](https://osteosarcomanow.org/stripe-checkout-result/)
- [Products](https://osteosarcomanow.org/products/)
- [Shop](https://osteosarcomanow.org/shop/)
- [Single Study](https://osteosarcomanow.org/single-study/)
- [What is a Clinical Trial](https://osteosarcomanow.org/what-is-a-clinical-trial/) - Clinical trials are essential to discover new treatments for people affected by osteosarcoma. Find out more about clinical trials and what they involve in our toolkit.
- [Contact Us](https://osteosarcomanow.org/contact-us/) - [et_pb_section fb_built=”1″ _builder_version=”4.14.4″ _module_preset=”default” custom_padding=”34px||34px||true|” global_colors_info=”{}”][et_pb_row _builder_version=”4.14.4″ _module_preset=”default” custom_padding=”5px||5px||true|” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https://osteosarcomanow.org/wp-content/uploads/2022/03/Contact-us-banner.png” title_text=”Contact us banner” align=”center” disabled_on=”on|off|off” _builder_version=”4.14.4″ _module_preset=”default” custom_margin=”||1px|||” global_colors_info=”{}”][/et_pb_image][et_pb_image src=”https://osteosarcomanow.org/wp-content/uploads/2022/03/About-Us-icon-with-circle.png” title_text=”About Us icon with circle” align=”center” disabled_on=”off|on|on” _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][/et_pb_image][/et_pb_column][/et_pb_row][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.14.4″ _module_preset=”default” custom_padding=”0px||18px|||” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.14.4″ _module_preset=”default” custom_margin=”-97px||||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.14.4″ _module_preset=”default”
- [Frequently Asked Questions](https://osteosarcomanow.org/frequently-asked-questions-2/) - Welcome to our Frequently Asked Question page. Here we provide the answers to common questions about clinical trials including the advantages and disadvantages.
- [What is Osteosarcoma](https://osteosarcomanow.org/what-is-osteosarcoma/) - Welcome to our Osteosarcoma Toolkit. Here you will find information about what osteosarcoma is, its symptoms and how it is diagnosed and treated.
- [TOOLKIT QUESTIONS TEST](https://osteosarcomanow.org/53297-2/) - [et_pb_section fb_built=”1″ _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ use_custom_gutter=”on” gutter_width=”1″ make_equal=”on” _builder_version=”4.14.4″ _module_preset=”default” width=”100%” module_alignment=”center” custom_padding=”0px||0px||true|” locked=”off” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.14.4″ _module_preset=”default” background_image=”https://osteosarcomanow.org/wp-content/uploads/2021/12/Layer-145.png” custom_padding=”200px||200px||true|false” global_colors_info=”{}”][et_pb_divider color=”RGBA(255,255,255,0)” _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][/et_pb_divider][/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.14.4″ _module_preset=”default” background_color=”#eff5db” custom_padding=”40px|30px|40px|30px|true|true” global_colors_info=”{}”][et_pb_text _builder_version=”4.14.4″ _module_preset=”default” text_font=”Poppins||||||||” text_text_color=”#000000″ text_font_size=”15px” text_line_height=”1.6em” text_orientation=”center” global_colors_info=”{}”] ANSWER FOR QUESTION 2 [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
- [Patients Toolkit](https://osteosarcomanow.org/patients-toolkit/) - [et_pb_section fb_built=”1″ _builder_version=”4.14.4″ _module_preset=”default” custom_padding=”34px||34px||true|” global_colors_info=”{}”][et_pb_row _builder_version=”4.14.4″ _module_preset=”default” custom_padding=”5px||5px||true|” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https://osteosarcomanow.org/wp-content/uploads/2021/12/Graphic.png” title_text=”Graphic” align=”center” disabled_on=”on|off|off” _builder_version=”4.14.4″ _module_preset=”default” custom_margin=”||1px|||” global_colors_info=”{}”][/et_pb_image][et_pb_image src=”https://osteosarcomanow.org/wp-content/uploads/2021/12/Graphic-1.png” title_text=”Graphic” align=”center” disabled_on=”off|on|on” _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][/et_pb_image][/et_pb_column][/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.14.4″ _module_preset=”default” custom_padding=”0px||18px|||” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.14.4″ _module_preset=”default” text_font=”Poppins|300|||||||” text_font_size=”20px” custom_padding=”|20px||34px|false|false” global_colors_info=”{}”] Below you’ll find various guides and suggestions
- [Result](https://osteosarcomanow.org/result/)
- [Type of Scan](https://osteosarcomanow.org/type-of-scan/) - There are many types of medical scans that are used to view different things. Here we explain the common scans you may have during your osteosarcoma journey.
- [Accessing Medical Records](https://osteosarcomanow.org/accessing-medical-records/) - In most countries, you can access your medical records. This page provides an overview of why you may want your medical records and how you can request them.
- [Getting a Second Opinion](https://osteosarcomanow.org/getting-a-second-opinion/) - This resource provides information to help you decide whether to seek a second opinion about treatment options for osteosarcoma and how to go about it.
- [Can't Find a Clinical Trial?](https://osteosarcomanow.org/cant-find-a-clinical-trial/) - [et_pb_section fb_built=”1″ _builder_version=”4.14.4″ _module_preset=”default” custom_padding=”34px||34px||true|” global_colors_info=”{}”][et_pb_row _builder_version=”4.14.4″ _module_preset=”default” custom_padding=”5px||5px||true|” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https://osteosarcomanow.org/wp-content/uploads/2021/12/Graphic1.png” title_text=”Graphic1″ align=”center” disabled_on=”on|off|off” _builder_version=”4.14.4″ _module_preset=”default” custom_margin=”||1px|||” global_colors_info=”{}”][/et_pb_image][et_pb_image src=”https://osteosarcomanow.org/wp-content/uploads/2021/12/clinincal-trials.png” title_text=”clinincal trials” align=”center” disabled_on=”off|on|on” _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][/et_pb_image][/et_pb_column][/et_pb_row][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.14.4″ _module_preset=”default” custom_padding=”0px||18px|||” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.14.4″
- [Template Page](https://osteosarcomanow.org/template-page/) - [et_pb_section fb_built=”1″ _builder_version=”4.14.4″ _module_preset=”default” custom_padding=”34px||34px||true|” global_colors_info=”{}”][et_pb_row _builder_version=”4.14.4″ _module_preset=”default” custom_padding=”5px||5px||true|” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https://osteosarcomanow.org/wp-content/uploads/2021/12/Graphic1.png” title_text=”Graphic1″ align=”center” disabled_on=”on|off|off” _builder_version=”4.14.4″ _module_preset=”default” custom_margin=”||1px|||” global_colors_info=”{}”][/et_pb_image][et_pb_image src=”https://osteosarcomanow.org/wp-content/uploads/2021/12/clinincal-trials.png” title_text=”clinincal trials” align=”center” disabled_on=”off|on|on” _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][/et_pb_image][/et_pb_column][/et_pb_row][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.14.4″ _module_preset=”default” custom_padding=”0px||18px|||” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.14.4″
- [coming soon](https://osteosarcomanow.org/coming-soon/) - [et_pb_section fb_built=”1″ _builder_version=”4.14.4″ _module_preset=”default” background_color=”#96c11e” custom_padding=”45vh||45vh||true|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.14.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.14.4″ _module_preset=”default” header_2_font=”Montserrat|600|||||||” header_2_text_align=”center” header_2_text_color=”#FFFFFF” header_2_font_size=”36px” global_colors_info=”{}”] Website in Development [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

## Events

- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-22/) - This week Dr Eunice Lopez Fuentes, will discuss her work studying two epigenetically distinct cellular states in osteosarcoma. Click on the title to find out more and register.
- [In-person Stories From the Stage: Living with Cancer](https://osteosarcomanow.org/event/in-person-stories-from-the-stage-living-with-cancer/) - Cancer impacts everyone. At this event storytellers, patients, doctors, and researchers will share their lived experiences with healthcare disparities, self-advocacy and highlight cancer equity initiatives. Click on the title to find out more and register.
- [OsteoBites webinar](https://osteosarcomanow.org/event/osteobites-webinar-24/) - During this week's webinar, Dr. Parthasarathy will discuss virtual surgical planning and 3D printing in surgery for children. Click on the title to find out more and register.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-23/) - Bang H. Hoang, MD from the University Hospital for Albert Einstein College of Medicine will discuss his work studying SCF-Skp2 protein complex as a therapy for osteosarcoma. Click on the title to find out more and register.
- [Bone Cancer Awarness Week](https://osteosarcomanow.org/event/bone-cancer-awarness-week/) - This week is Bone Cancer Awareness Week. Get involved on social media using #BoneCancerAwarenessWeek.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-21/) - This week Dr Leibowitz will discuss his research on cell-based therapies for osteosarcoma. Click on the title to find out more and register.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-20/) - This week Dr Gounder will discuss how cancer genetics affects the management of soft tissue and bone sarcoma. Click on the title to find out more and register.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-19/) - Dr Sharma and Dr Kim will be discussing the use of interventional radiology for osteosarcoma. Click on the title to find out more and register.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-18/) - This week Dr Dan Regan will be discussing his work looking at focal adhesion kinase (FAK) inhibition to improve losartan-sunitinib in metastatic osteosarcoma. Click on the title to find out more and register.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-17/) - This week Dr Nacev will be providing updates on the genetics of 2,138 bone and soft tissue sarcomas and how this can help inform research into new treatments. Click on the title to find out more and register.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-16/) - This week Dr Kinnaman will be talking about how osteosarcoma evolves from diagnosis to relapse. Click on the title to find out more and register.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-14/) - This week one of our grant holders Dr Nancy DeMore will be sharing information about her work on overcoming PD-1 inhibitor resistance in Metastatic Osteosarcoma. Click on the title to find out more and register.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-15/) - This week Dr Sam Volchenboum will discuss the Pediatric Cancer Data Commons and what we can learn from it. Click on the title to find out more and register.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-13/) - This week Dr Nathalie Gaspar will be providing an update on a clinical trial looking at lenvatinib in children and adolescents with osteosarcoma. Click on the title to find out more and register.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-12/) - This week Dr Canter will discuss the use of inhaled IL-15 to treat dogs with naturally occurring lung metastases from osteosarcoma. Click on the title to find out more and register.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-11/) - Dr Jason Yustein will share his research looking at combination therapies for osteosarcoma. The studies will provide essential information to direct future clinical trials. Click on the title to find out more and register.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-10/) - Dr John A. Ligon ( University of Florida College of Medicine) will discuss his research using RNA-nanoparticle vaccines to overcome the immunosuppressive tumour microenvironment of osteosarcoma in dogs. Click on the title to find out more and register.
- [Race to Cure Sarcoma (USA Virtual)](https://osteosarcomanow.org/event/race-to-cure-sarcoma-usa-virtual/) - The Sarcoma Foundation of America invites you to take part in the National Race to Cure Sarcoma Virtual event. Run, jog, or walk 5k to help raise awareness and funds for sarcoma research. Click on the title to find out more.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-8/) - MIB Agents, a charity dedicated to the osteosarcoma community, host regular webinars discussing the science of osteosarcoma and current research. In today’s webinar Professor Katherine Janeway (Dana Fabre) will be sharing an update on a phase 2 clinical trial for recurrent osteosarcoma. Click on the title to find out more and register.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-9/) - MIB Agents, a charity dedicated to the osteosarcoma community, host regular webinars discussing the science of osteosarcoma and current research. In today’s webinar Brenna Carswell will be discussing paediatric clinical trials and how to navigate them. Click on the title to find out more and register.
- [Stand Up to Sarcoma Gala](https://osteosarcomanow.org/event/stand-up-to-sarcoma-gala/) - The Sarcoma Foundation of America's is hosting its 20th Annual Fundraiser. Proceeds from the event will be used to fund research into sarcoma and create patient education programmes. Click on the title to find out more.
- [Sarkomföreningen Sarcoma Day (Sweden)](https://osteosarcomanow.org/event/sarkomforeningen-sarcoma-day-sweden/) - Sarkomföreningen (The Swedish Sarcoma Association) is hosting an in-person event for people in Sweden affected by sarcoma. Doctors, nurses, researchers, and patients advocates will be present at the event with plenty of time for questions and discussions. Topics include Relapse and Anxiety and Sarcoma Research. Click on the title to find out more.
- [BCRT Bone Cancer Conference](https://osteosarcomanow.org/event/bcrt-bone-cancer-conference-2/) - The BCRT (UK) are hosting their award-winning day of inspiration & support. The event is open to all of the primary bone cancer community. The events will include research updates, patient talks, information and support resources. Click on the title to find out more.
- [BCRT Bone Cancer Conference](https://osteosarcomanow.org/event/bcrt-bone-cancer-conference/) - The BCRT (UK) are hosting their award-winning day of inspiration & support. The event is open to all of the primary bone cancer community. The events will include research updates, patient talks, information and support resources. Click on the title to find out more.
- [2022 SPAEN Patient Advocate Annual Conference](https://osteosarcomanow.org/event/2022-spaen-patient-advocate-annual-conference/) - Sarcoma Patient EuroNet runs a yearly conference for sarcoma patient advocates. This year the event will be held in person and online. The conference will cover a range of topics including research updates in sarcoma and discussions about standards of excellence for patient organisations. Click on the title to find out more.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-7/) - MIB Agents, a charity dedicated to the osteosarcoma community, host weekly webinars discussing the science of osteosarcoma and current research. In today’s webinar, Dr Omer will be discussing a type of drug called "Armored" CAR T cells for Osteosarcoma. Click on the title to find out more.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-4/) - MIB Agents, a charity dedicated to the osteosarcoma community, host weekly webinars discussing the science of osteosarcoma and current research. This week Dr Alex Huang and Dr Kristen VanHeyst will be sharing an update on clinical trial development targeting tumour microenvironment in refractory and metastatic osteosarcoma. Click on the title to register and find out more.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-5/) - MIB Agents, a charity dedicated to the osteosarcoma community, host weekly webinars discussing the science of osteosarcoma and current research. This week Dr Painter shares an update on the Count Me In Osteosarcoma Project. An exciting project collecting data from osteosarcoma patients to better understand and treat osteosarcoma. Click on the title to register and find out more.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-6/) - MIB Agents, a charity dedicated to the osteosarcoma community, host weekly webinars discussing the science of osteosarcoma and current research. In today's webinar Dr Breelyn Wilky (University of Colorado Anschutz Medical Campus) will be discussing Immunotherapy for Osteosarcoma. Immunotherapy is a type of cancer treatment that used the immune system to attack cancer cells. Click on the title to register and find out more.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-3/) - MIB Agents, a charity dedicated to the osteosarcoma community, host weekly webinars discussing the science of osteosarcoma and current research. This week Dr Brooke Bernhardt from Baylor College of Medicine will be sharing information about exploring the use of a predictive tool for methotrexate clearance. Click on the title to find out more and register.
- [British Sarcoma Group Annual Conference](https://osteosarcomanow.org/event/british-sarcoma-group-annual-conference/) - A yearly conference set up by the British Sarcoma Group aimed at researchers and clinicians to discuss developments in sarcoma research. Click on the title to find out more.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar/) - MIB Agents, a charity dedicated to the osteosarcoma community, host weekly webinars discussing the science of osteosarcoma and current research. This week Doctor Amanda Marinoff will be discussing her research investigating the protein MYC and how it may be used to predict outcomes in osteosarcoma. Register now.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webiar/) - MIB Agents, a charity dedicated to the osteosarcoma community, host weekly webinars discussing the science of osteosarcoma and current research. This week Elena Gerasimov will be discussing compassionate use programmes. Register now.
- [OsteoBites webinar](https://osteosarcomanow.org/event/osteobites-webinar-2/) - MIB Agents, a charity dedicated to the osteosarcoma community, host weekly webinars discussing the science of osteosarcoma and current research. This week Dr Vishu Avutu will discuss a new clinical trial looking at the drugs ZN-c3 Plus Gemcitabine to treat metastatic osteosarcoma. Register now.
- [Rare Cancer Day](https://osteosarcomanow.org/event/rare-cancer-day/) - A day to raise awareness of rare cancers. We will be posting on social media and talking about osteosarcoma.
- [Worlds Biggest Coffee Morning](https://osteosarcomanow.org/event/worlds-biggest-coffee-morning/) - A yearly event in the UK to raise money for the cancer charity Macmillan. People all over the UK host their own Coffee Morning and donations raised on the day are made to Macmillan. Find out more here.
- [Sarcoma Awareness Month](https://osteosarcomanow.org/event/sarcoma-awareness-month/) - Sarcoma Awareness Month runs throughout July and aims to raise awareness of sarcomas. We will be creating a detailed itinerary of events you can get involved in soon.
- [AACR Sarcoma Conference](https://osteosarcomanow.org/event/aacr-sarcoma-conference/) - This American Association for Cancer Research is hosting a conference on sarcomas for doctors and researchers. This conference will provide a platform for reviewing the evidence of the cause and progression of sarcomas, in addition to examining the current and novel therapies. Find out more here or click on the link below.
- [OsteoBites Webinar](https://osteosarcomanow.org/event/osteobites-webinar-the-prophylactic-antibiotic-regimens-in-tumor-surgery-parity-international-randomized-controlled-trial/) - MIB Agents, a charity dedicated to the osteosarcoma community, host weekly webinars discussing the science of osteosarcoma and current research. This week webinar is titled The Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) International Randomized Controlled Trial. Dr. Michelle Ghert, Professor of Surgery at McMaster University, will present her research exploring the best antibiotic regimes
- [MIB Factor Conference](https://osteosarcomanow.org/event/mib-factor-conference/) - MIB Agents will be hosting their MIB Factor Conference this June in San Diego, California and online. This hybrid event brings together patients, clinicians and researchers to discuss ways to improve outcomes in osteosarcoma and raise awareness of the condition. Find out more here or click on the link below.
- [National Cancer Research Month](https://osteosarcomanow.org/event/national-cancer-research-month/) - May is National Cancer Research Month. It is a global awareness campaign highlighting the importance of cancer research to improve outcomes for those diagnosed with cancer. Visit the ACCR to see how you can get involved or click on the link below.
- [Cancer Immunotherapy Month](https://osteosarcomanow.org/event/cancer-immunotherapy-month/) - June is Cancer Immunotherapy Month. Immunotherapy is a type of cancer therapy that uses the bodies immune system to kill cancer cells. The cancer research initiative is hosting a number of events including webinars and patient stories. Find out more here or click on the link below.
- [2022 Minnesota Sarcoma Research Conference: Progress and Promise](https://osteosarcomanow.org/event/2022-minnesota-sarcoma-research-conference-progress-and-promise/) - Join leaders in Sarcoma research talking about current developments and future research strategies. The event will be held in person at the University of Minnesota and online and is aimed at researchers and Rein in Sarcoma stakeholders. Find out more here or click on the link below.
- [Test event Testing event](https://osteosarcomanow.org/event/test-event-testing-event/) - Test event Testing eventTest event Testing event

## Categories

- [Uncategorized](https://osteosarcomanow.org/category/uncategorized/)
- [Research](https://osteosarcomanow.org/category/research/)
- [Resources and Support](https://osteosarcomanow.org/category/resources-and-support/)
- [Clinical Trials](https://osteosarcomanow.org/category/clinical-trials/)
- [ONTEX](https://osteosarcomanow.org/category/ontex/)

## Tags

- [Research](https://osteosarcomanow.org/tag/research/) - Research
- [Osteosarcoma research](https://osteosarcomanow.org/tag/osteosarcoma-research/) - Osteosarcoma research
- [Osteosarcoma modelling](https://osteosarcomanow.org/tag/osteosarcoma-modelling/) - Osteosarcoma modelling
- [Clinical Trials](https://osteosarcomanow.org/tag/clinical-trials/) - Clinical Trials
- [Osteosarcoma](https://osteosarcomanow.org/tag/osteosarcoma/) - Osteosarcoma
- [bardo](https://osteosarcomanow.org/tag/bardo/) - bardo
- [Bardo Foundation](https://osteosarcomanow.org/tag/bardo-foundation/) - Bardo Foundation